SUMOylation in Glioblastoma: A Novel Therapeutic Target

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Apr 18

PMID 30991648

Citations 10

Authors

Brandon M Fox

Andrew Janssen

Dagoberto Estevez-Ordonez

Florian Gessler

Nunzio Vicario

Gustavo Chagoya

Galal Elsayed

Houman Sotoudeh

William Stetler

Gregory K Friedman

Joshua D Bernstock

Affiliations

Soon will be listed here.

Abstract

Protein SUMOylation is a dynamic post-translational modification which is involved in a diverse set of physiologic processes throughout the cell. Of note, SUMOylation also plays a role in the pathobiology of a myriad of cancers, one of which is glioblastoma (GBM). Accordingly, herein, we review core aspects of SUMOylation as it relates to GBM and in so doing highlight putative methods/modalities capable of therapeutically engaging the pathway for treatment of this deadly neoplasm.

Citing Articles

Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma.

Min Z, Guo Y, Ning L Front Pharmacol. 2024; 15:1490878.

PMID: 39723246 PMC: 11668589. DOI: 10.3389/fphar.2024.1490878.

Roles of posttranslational modifications in lipid metabolism and cancer progression.

Feng T, Zhang H, Zhou Y, Zhu Y, Shi S, Li K Biomark Res. 2024; 12(1):141.

PMID: 39551780 PMC: 11571667. DOI: 10.1186/s40364-024-00681-y.

SENP7 inhibits glioblastoma metastasis and invasion by dissociating SUMO2/3 binding to specific target proteins.

Zhang J, Zheng H, Liang P Open Med (Wars). 2024; 19(1):20241052.

PMID: 39381427 PMC: 11459272. DOI: 10.1515/med-2024-1052.

Glioblastoma mesenchymal subtype enhances antioxidant defence to reduce susceptibility to ferroptosis.

DAprile S, Denaro S, Lavoro A, Candido S, Giallongo S, Torrisi F Sci Rep. 2024; 14(1):20770.

PMID: 39237744 PMC: 11377710. DOI: 10.1038/s41598-024-72024-8.

Impacts of Nutlin-3a and exercise on murine double minute 2-enriched glioma treatment.

Chen Y, Fan Z, Luo Z, Kang X, Wan R, Li F Neural Regen Res. 2024; 20(4):1135-1152.

PMID: 38989952 PMC: 11438351. DOI: 10.4103/NRR.NRR-D-23-00875.

References

Gong L, Li B, Millas S, Yeh E . Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett. 1999; 448(1):185-9. DOI: 10.1016/s0014-5793(99)00367-1. View

Gong L, Millas S, Maul G, Yeh E . Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J Biol Chem. 2000; 275(5):3355-9. DOI: 10.1074/jbc.275.5.3355. View

Zhong S, Muller S, Ronchetti S, Freemont P, Dejean A, Pandolfi P . Role of SUMO-1-modified PML in nuclear body formation. Blood. 2000; 95(9):2748-52. View

Yeh E, Gong L, Kamitani T . Ubiquitin-like proteins: new wines in new bottles. Gene. 2000; 248(1-2):1-14. DOI: 10.1016/s0378-1119(00)00139-6. View

Rodriguez M, Dargemont C, Hay R . SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem. 2001; 276(16):12654-9. DOI: 10.1074/jbc.M009476200. View

Sampson D, Wang M, Matunis M . The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem. 2001; 276(24):21664-9. DOI: 10.1074/jbc.M100006200. View

Ling Y, Donato N, Perez-Soler R . Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemother Pharmacol. 2001; 47(6):473-80. DOI: 10.1007/s002800000239. View

Johnson E, Gupta A . An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell. 2001; 106(6):735-44. DOI: 10.1016/s0092-8674(01)00491-3. View

Mo Y, Yu Y, Shen Z, Beck W . Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J Biol Chem. 2001; 277(4):2958-64. DOI: 10.1074/jbc.M108263200. View

10.

Pichler A, Gast A, Seeler J, Dejean A, Melchior F . The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell. 2002; 108(1):109-20. DOI: 10.1016/s0092-8674(01)00633-x. View

11.

Rapisarda A, Uranchimeg B, Scudiero D, Selby M, Sausville E, Shoemaker R . Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002; 62(15):4316-24. View

12.

Bohren K, Nadkarni V, Song J, Gabbay K, Owerbach D . A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem. 2004; 279(26):27233-8. DOI: 10.1074/jbc.M402273200. View

13.

Wang L, Banerjee S . Differential PIAS3 expression in human malignancy. Oncol Rep. 2004; 11(6):1319-24. View

14.

Maeda D, Seki M, Onoda F, Branzei D, Kawabe Y, Enomoto T . Ubc9 is required for damage-tolerance and damage-induced interchromosomal homologous recombination in S. cerevisiae. DNA Repair (Amst). 2004; 3(3):335-41. DOI: 10.1016/j.dnarep.2003.11.011. View

15.

Johnson E . Protein modification by SUMO. Annu Rev Biochem. 2004; 73:355-82. DOI: 10.1146/annurev.biochem.73.011303.074118. View

16.

Ledl A, Schmidt D, Muller S . Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene. 2005; 24(23):3810-8. DOI: 10.1038/sj.onc.1208539. View

17.

Owerbach D, McKay E, Yeh E, Gabbay K, Bohren K . A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun. 2005; 337(2):517-20. DOI: 10.1016/j.bbrc.2005.09.090. View

18.

Bouillot-Eimer S, Loiseau H, Vital A . Subcutaneous tumoral seeding from a glioblastoma following stereotactic biopsy: case report and review of the literature. Clin Neuropathol. 2005; 24(6):247-51. View

19.

Nakayama K, Nakayama K . Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006; 6(5):369-81. DOI: 10.1038/nrc1881. View

20.

Kim J, Choi H, Kim B, Kim M, Lee J, Kim I . Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat Cell Biol. 2006; 8(6):631-9. DOI: 10.1038/ncb1415. View